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S ry Death from cancer results from the devlopment of metastases or local p on of tumour.
Metastasis and local pogresson may result from the inappropte activty of metalloprotenases rlased by
ther regulatory peptides. We have developed quantitative assays for interstitial collagenase,
stromelysin I and tissue inhibitors of metalloproteinase (TMP) I and 2, which have allowed the study of
serum kves of these proteins. Sera from 40 patients with prostabc cancer, stored prior to and after 6 and 12
months' treatment with a gonadotrophin-releasing hormone agonist and an anti-androgen were analysed.
Levels were compared with two control groups, comprising 21 patients with active rheumatoid arthritis and 56
age-matched hospital attenders without arthritis or cancer. Contrsting kvels have been found in patients with
prostatic cancer as compared with hospital controls without cancer and patients with rheumatoid arthritis.
Patients with prostatic cancer had higher kvels of TIMP-1 and collagenase (P = 0.0001) and lower levels of
TIMP-2 (P = 0.003) than controk. Patients with metastatic cancer had sigficantly higher klvs of clanase
than those without meastases (P = 0.02). Patients with rheumatoid arthritis had signifintly higher leviels of
stromelysin than either controls (P = 0.002) or patients with cancer (P = 0.008). Serum tissue inhibitor of
metalloprotenase 1 in combination with collagnase kvs was as sensitive as prostate-specific antigen as a
marker of metastatic disea. Tese findings provide a basis for the investigation of the role of metallo-
proteinases and ther inhibitors in other malignances.
In a study of 750,000 patients with malignancy, approxi-
mately half of the patients who presented with apparently
localised tumours subsequently died of metastases (Sugar-
baker, 1981). A major challenge for oncological practice is
the identification of these patients with micrometastases at
their initial presentation. The availability of more specific
markers for micrometastases might then allow for the
rational introduction of adjuvant chemotherapy or novel
biological therapies and improve the prognosis (Waxman &
Wasan, 1992).
It is postulated that the progression of cancer may be the
result of the activity of proteinases that facilitate invasion
and metastasis by degrading the extraceliular tissue matrix.
One group of proteinases, the tissue metalloproteinases, are a
widely distributed family of enzymes which play a key role in
the turnover and remodelling of the connective tissue matrix.
The metalloproteinases are classified according to their sub-
strate specificity and include interstitial and neutrophil
coilagenase, stromelysins 1-3, gelatinase A and B and mat-
rilysin. The enzymes are tightly regulated through control of
gene expression and at a post-translational level are activated
by cleavage of a propeptide. Two specific inhibitors of
metalloproteinases (TTMPs 1 and 2) have been sequenced
and cloned. There is disregulation of the metalloproteinases
in cancer and in the arthritides (Liotta et al, 1991; Docherty
et al., 1992).
We have developed enzyme-hinked immunoassays (ELISAs)
for the measurement of interstitial coliagenase, stromelysin 1
and TIMP-1 and -2 and applied these assays to the serum of
patients with prostate cancer, attempting to distinguish
between metastatic and non-metastatic disease, and investi-
gating whether levels reflect tumour responsiveness to hor-
monal therapy. Levels have been compared with controls
without cancer and patients with rheumatoid arthritis, in
order to examine whether there are distinctive profiles in
these conditions, reflecting different modes of connective tis-
sue remodelling.
Pafiemts, aat m
Bloodsampling
In the prostatic cancer patients phlebotomy was performed
prior to treatment, and sequentially at 6 monthly intervals.
In all patients and control groups samples were colleted in
plain glass bottles, serum was separated by centrifugation
after coagulation, and then stored at -40C.
Study groups
Prostate cancer Serum samples were analysed from 40
patients with prostatic cancer. Twenty-two patients had
metastatic disease and 18 localised tumours. Five patients
with prostatic cancer were then excluded from the analysis
because of the development of second tumours in four
patients and a sampling error in a fifth. Nimeteen metastases-
positive and 16 metastases-negative patients were studied. All
patients with prostatic cancer were treated with buserelin, a
gonadotrophin-releasing hormone (GnRH) agonist given at a
dosage of 3mg, 6.6mg or 1Omg every 1, 2 or 3 months
(Waxman et al., 1989). Patients were staged according to the
classification of the Union Internationale Contre Le Cancer
(UICC, 1978) and restaged every 6 months. Tumours were
graded according to the Gleason system. Responses were
classified according to the criteria of the National Prostatic
Cancer Project (Torti, 1983).
Rheunatoid arthritis Sera from 21 patients with active
rheumatoid arthritis whose disease fulfilled the revised
criteria of the American Rheumatology Association (Arnett
et al., 1988) were used for this analysis.
Controls Fifty-seven patients attending the Hammersmith
Hospital Outpatients Department for non-malignant and
non-rheumatoid conditions constituted the control group.
One of these patients was subsequently found to have thyroid
cancer and was excluded from the analysis. Sera from these
patients were stored at -40-C, and used for this analysis.
Reagents
Antibodes Murine monoclonal antibodies were raised to
natural human TIMP-l (code MAC15 and MAC19), col-
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lagnase (code MAC64 and MAC66) and stromelysin (code
MAC78) and rabbit antiserum was raised human
stromelysin (Cooksley et al., 1990). A similar procedure was
used to raise a monoclonal to recombinant TEMP-2 (code
MAC93). Antibodie MAC15 and MAC66 were biotinylated
(Cooksley et al., 1990). Sheep antiserwn raised against
human TIMP-2 was a gift from G. Murphy, Strangeways
Research Laboratories, Cambridge. The initial selection of
antibodies was based on their ability to show specific binding
with the n t enzyme or inhibitor when tested by
Western blotting against a panel of related metallo-
proteinases and TIMPs (data available on request).
Enzymes Recombinant human proteins were produced from
cDNAs encoding human procollagnase, prostromelysin and
TTMPs transfected into mammalian cells (Docherty et al.,
1985; Murphy et al., 1987).
Conjugates Donkey anti-rabbit IgG-peroxidase and anti-
sheep IgG-peroxidase were obtained from Jackson Immuno-
reearch. Streptavidin-peroxidaw conjugate (Ceiltech) was
prepared as a 1 jIgml-' solution in phosphate-buffered saline
containing 2% (v/v) heat-inactvated fetal calf serum (FCS;
supplied by Gibco), 0.1% (w/v) thimerosal (Sigma), 0.01%
(w/v) 3,3',5,5'-tetramethylbenzidine (TMB, supplied by ICN)
and 0.01% brilliant blue FCF (Sigma).
Diluents Assay diluent was 0.1 M Tris-base, 0.1 M sodium
chloride, 0.05% Tween 20, adjusted to pH 7.4 with concen-
trated hydrochlonc acid. Conjugate diuent contained 2%
FCS in phosphate-buffered sahne.
Substrate Substrate consisted of 0.01% (w/v) TMB, 1.0%
dimethylsulphoxide (v/v), 0.25% (w/v) A-cyclodextrin and
0.005% (v/v) hydrogen peroxide in 0.1 M acetate buffer
(pH 5.0).
Standards Purified recombinant human proteins were pro-
duced from cDNAs encoding humn procollagnase, pro-
stromelysin and TIMPs transfcted into mammalian cells
(Docherty et al., 1985; Murphy et al., 1987). Standards were
prepared at 0, 3.16, 10, 31.6, 100, 316, 1,000 and 3,162 ngm[-l
in assay diluent [0.1 M Trs-HC, 0.1 M sodium chloride,
0.019 (v/v) Tween 20, pH 7.4] subaliquoted and stored at
-70'C prior to use.
TIMP-) reagents Microwell plates (Nunc immunoplate 1)
were coated overnight with MAC19 at 5.0 gml-' (200#l
per well) in 0.05 M carbonate buffer (pH 9.6). The plates were
blocked for 1 h with 0.2% protease-free bovine serm
albumin (BSA) (Sigma). Sample diluent contained 0.1% nor-
mal mouse serum (NMS) and 1.0% protease-free BSA in
assay diluent. The revealing antibody was biotinylated
MAC15 used at a concentration of 0.5jgml-' in sample
diluent. The conjugate was streptavidin-peroxidase at a con-
centration of 0.062ggml-' in conjugate diluent.
TIMP-2 reagents The solid phase reagent comprised micro-
well plates coated and blocked as above but with MAC93
coated at 1.0 agml-'. The sample dihuent contained 1.0%
NMS, 1.0% protease-free BSA and 5.0% FCS in assay
diuent. The revealing antibody was anti-TIMP-2 IgG at
1 pggml-' in sample diluent and the conjugate donkey anti-
sheep IgG-peroxidase diluted to 1:20,000 in conjugate
diluent.
Stromelysin reagents The solid phase reagent comprised
microwell plates coated and blocked as above but with
MAC78 coated at 5.0 gml-'. The sample diluent consisted
of 0.1% NMS, 1.0% protease-free BSA and 5.0% normal
horse serum in assay diluent. The revealing reagent was
rabbit anti-stromelysin IgG at 5.0pjgml-' in sample diluent
and the conjugated anti-rabbit IgG-peroxidase diluted to 1/
20,000 in conjugate diluent.
Collagenase reagents The solid phase reagent comprised
microwell plates coated and blocked as above but with
MAC64 coated at 5.0jgml-' in phosphate-buffered saline.
The sample diluent contained 0.1% NMS and 5.0% FCS in
assay diluent. Biotinylated MAC66 at 0.25jigml-' in sample
diluent was the revealing reagent. Conjugate, streptavidin-
peroxidase, was used at 0.25pgml-' in conjugate diluent.
ELISA method Antibodies at 5 gml-' (MAC93 1 jugml-')
in 0.05 M carbonate buffer, pH 9.6, were used to coat (200gpl
for 18 h at 20-C) microwell plates (Nunc immunoplates) for
the ELISAs. These were MAC19 (TIMP-1), MAC93 (TIMP-
2), MAC78 (stromeysin) and MAC64 (collagenase). Wells
were then blocked (400gal, 1 h) with 0.2% (w/v) protease-free
BSA in coating buffer.
For TIMP-, TIMP-2, colagnase and stromeysin ELISAs,
10 gl of sample (in duplicate) or standard (in triplicate) was
added to a coated microwell followed by 200 Id of sample
diluent [assay diluent containing 1% BSA (excepting col-
lagenase), 0.01% mouse serum (1% for TIMP-2), 5% FCS
(TIMP-2 and collagnase) and 5% horse serum (stromely-
sin)]. The wells were sealed and incubated for 1 h at 20-C
with orbital shaking of the plate (300 r.p.m.), then washed
with 4 x 400 j1 of assay diluent.
Second and third incubation and wash stages were run
under similar conditions employing 200 jlI aliquots of the
following revealing antibody and conjugate solution: for
TIMP-1 and collagnase, biotinylated antibodies, MAC1S
(0.5jigml') and MAC66 (0.25jgml-') in sample diluent in
combination with streptavidin-peroxidase conjugate (Cell-
tech Ltd) at 0.062/0.25 jigml-' in conjugate diluent (2% FCS
in assay diluent); for TIMP-2 and stromelysin, polyclonal
IgG, anti-TIMP-2 (1jigml-') and anti-stromelysin
(0.5jgml-') in sample diluent were used in combination
with anti-species IgG-peroxidase conjugates (Jackson
Immunoresearch) at 1 in 20,000 in conjugate diluent.
Colour development required a 0.5h incubation with a
substrate mixture comprising 0.01% (w/v) 3,3',5,5'-tetra-
methylbenzidine (ICN), 1.0% (v/v) dimethylsulphoxide and
0.25% (w/v) P-cyclodextrin (Sigma) and 0.005% (v/v) hy-
drogen peroxide (BDH) in 0.1 M acetate buffer (pH 5.0) and
was stopped by the addition of 50j1 of 2.5% sodium
fluoride. Absorbance (630nm) was measured using a Biotek
EL31O plate reader (reference wavelength at 490 nm) and the
data were reduced usng the Multicakc software package
(Pharmada), whereby absorbance of unknowns was inter-
polated from calibration curves ofabsorbance plotted against
molar concentration of the relevant metalloproteinase or
TIMP standard.
Serwm markers
Alkaline phosphatase, total acid phosphatase, prostatic acid
phosphatase and prostat-specific antigen were measured in
each serum sample as part of the routine biochemical screen-
ing of prostate cancer patients by the Department of
Chemical Pathology, Hammersmith Hospital.
Statistical methods
Data were analysed using a Statview-4 statisfical software
package. Two-tailed unpaired Student t-tests were performed,
except where indicated.
Res ts
Assay validation andperformance
The ELISAs were tested in a number of ways in order to
establish validity; these results are summarised in Table I. All
unknowns fell within the working range of the four ELISAs
with the exception of 11 undetectable serum collagnase
values. Repeat assays on 12 samples gave acceptable
between-assay precision. The assays were highly specific506 T. BAKER et al.
Table I Assay performance
ELISA Collagenase Stromelysin TIMP1 TIMP2
Limit of detection (nM) 0.15 0.10 0.09 0.15
(mean n assays) (8) (7) (6) (8)
Working range (nM) 0.32-24.0 1.09-17.23 1.03-35.2 1.09-17.2
(n assays) (6) (7) (8) (5)
Between-assay precision (% CV) 9.5 14.3 8.2 10.6
Recovery (%) 100-123 102-110 92-103 80-93
Potency (%)
Proenzyme 100 100 - -
Active enzyne 13.5 36.9
Active enzyme+ TIMP-l 13.5a 11.8a 6.Ob -
Active enzyme + TIMP-2 13.5a 43.8' -49b
Active enzyme + M2-macroglobulin 13.5' 36.9 - -
Cross-reactivity (%)
TIMPI ND ND 100 ND
TIMP2 ND ND ND 100
Procollagenase 100 ND ND ND
Prostromelysin ND 100 ND ND
Progelatinase A ND ND ND ND
Progelatinase B ND ND ND ND
Promatrilysin ND ND ND ND
c,-Macroglobulin ND ND ND ND
Interference
TIMP-1 100 100 - 100
TIMP-2 100 100 100 -
Procollagenase 1 100 100 100
Prostromelysin 100 - 100 100
Progelatinase A 100 100 100 20
Progelatinase B 100 100 20 100
Promatrilysin 100 100 100 100
a,-Macroglobulin 100 100 100 100
"Inhibitor present at 5-fold molar excess of enzyme. bEnzyme present at 5-fold molar excess of
inhibitor. Working range defined as dose range within which assay precision was < 10% CV.
Between-assay precision determined on repeat assay of 12 samples where analyte concentration
< 17 nm. Per cent recovery of analyte was determined by spiking pooled human serum with assay
standards. Cross-reactivity was detemined using 1 1zg mrl ' competitor in the absence of analyte and
interference was determined using I jugml-' competitor in the presence of 15-40ngml-' analyte; in
either case the measured result was expressed as a percentage of the measured analyte level alone. ND,
not detectable.
showing no cross-reactivity with other human metallopro-
teinases in the case ofcollagenase and stromelysin ELISAs or
the alternative inhibitor in the case of the TIMP-1 and
TIMP-2 ELISAs. The collagenase and stromelysin ELISAs
predominantly recognised the corresponding proenzyme, with
the activated enzyme or active enzyme inhibitor complexes
showing considerably reduced potency. Similarly, the TIMP-1
and TIMP-2 ELISAs recognise predominantly the free form
ofinhibitor; complexes with activated metalloproteinase were
not recognised and complexes with proforms of gelatinase
showed reduced potency.
Pretherapy prostate cancer serwn versus control serum groups
Figures 1 and 2 show the distribution of individual patients'
serum collagenase, stromelysin, TIMP-1 and TIMP-2 concen-
tration and derived ratios in cancer, rheumatoid and hospital
control groups. Means and standard deviations for each
group are shown together with between-group significant
differences. There were no sex-, renal function- or age-related
differences in metalloproteinases or TIMP levels within the
control group.
Serunmetalloproteinase concentrations
Mean baseline collagenase levels (Figure la) in the meta-
stasis-positive (0.38 aM) and -negative patients (0.23 nM) were
highly significantly different from the non-cancer control
group mean (0.1 nM) (P = 0.002). The metastasis-positive
mean was significantly increased (P=0.05, one-tailed test)
compared with the metastasis-negative mean.
The mean level in rheumatoid arthritis patients (0.26 nM)
was also significantly greater than the control mean
(P= 0.01) although not significantly different from either
cancer group.
In contrast, mean stromelysin levels (Figure Ib) were not
significantly different between the cancer (1.05 nM) and non-
cancer control (1.02 nM) groups, whereas in the rheumatoid
group mean stromelysin was raised over 3-fold (3.48 mM) as
compared with cancer patients (P = 0.001). Figure Ic shows
the molar ratio of collagenase to stromelysin in individual
serum samples. Both cancer groups, particularly metastasis-
positive patients (P = 0.0001), had significantly increased
ratios compared with the rheumatoid or hospital control
groups.
Serwn TIMP concentrations
Mean TIMP-1 concentration (Figure 2a) in the cancer
patients (12.9 nM) was highly significantly different from the
hospital control group (9.8 nM), but was not significantly
different from the rheumatoid group (11.7 rM). No difference
was observed between metastasis-positive and -negative
groups. In contrast, mean TIMP-2 levels (Figure 2b) were
lower in the prostatic cancer patients (3.1 nM) than in the
hospital controls (3.5 nM) (P=0.003) and rheumatoid
patients (4.8 nM) (P = 0.0001).
Figure Ic describes the ratio of TIMP-1 to TIMP-2. In
prostate cancer groups serum TIMP-1 was in 4-fold molar
excess over TIMP-2, falling to a 2.8-fold molar excess in the
control group and a 1.5-fold molar excess in the rheumatoid
group. The combined molarity of the two inhibitors was
some 10-fold greater than the combined enzyme molarity.
Metalloproteinses and TIMP levels duringprostate cancer
treatment
Figure 3 describes the temporal variation in means and stan-
dard deviations of metalloproteinase and TIMP levels in
prostate cancer patients during the first 12 months ofMETALLOPROTEINASES AND INHIBITORS AS MALIGNANCY MARKERS 569
buserelin treatment compared with pretreatment levels.
Patients were dividied into metastasis-negative (MO) and
metastasis-positive (Ml) groups according to clinical diag-
nosis at the corresponding time point. There was a significant
fall in collagnase levels in the MO (P= 0.015) and Ml
(P = 0.0002) groups, and in stromelysin in the Ml subgroup
(P = 0.03), at 6 months. TIMP-l mean levels showed a
highly significant drop after 6 months' therapy (P = 0.0002).
TIMP-2 levels increased in both groups after 6 months'
treatment (P = 0.004). Collagnase and stromelysin levels
remained depressed at 12 months oftherapy, whereas TIMP-
1 levels returned to baseline values.
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Predictive value analysis
Non-parametric predictive value analysis was carried out on
the baselne data in order to assess how each marker or
combination of markers might predict disease outcome
(Galen, 1984). A threshold value was selected for each
marker as the mid-value between the 75th percentile of the
lower group (MO) and the 25th percentile of the higher group
(MI). The distribution ofdata about each threshold was then
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FMge 1 Scatter photo showing the concentration of TIMPs in
serum from prostatic cancer patients with and without metastasis,
patients with rheumatoid arthntis and hospital controls. Each
point represents a single patient. The standard error for each
group is shown at the mean value. a, TIMP-l. b, TIMP-2. c,
Molar ratio of TIMP-1 to TIMP-2. The molar concentrations
were determined using molecular weights of 28 kDa for TIMP-l
and 21 kDa for TIMP-2. The brackets indicate significant
differences between groups as determined by Student's t-test
a = P<O.OO1; b = P<0.005; c = P<O.O1; d = P<0.05.
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Fgw 2 Scatter photo showing the concentration of collagenase
and stromelysin in serum from prostatic cancer patients with and
without metastasis, patients with rheumatoid arthritis and hos-
pital controls. Each point represents a single patient. The stan-
dard error for each group is shown at the mean value. a, Col-
lagenase. b, Stromelysin- c, The molar ratio of collagenase to
stromelysin. The molar concentrations were determined using
mokcular weights of 56 kDa for both collagenase and
stromelysin. Five patients from the metastasis-positive group and
five patients from the rheumatoid group had undetectable klvels
of colgenase and hence had no ratio value. The brackets
indicate significant differences between groups as determined by
Student's t-test: a = P<O.OO1; b = P<0.005; c = P<O.O1;
d = P<0.05.
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compared with metastasis category at the 12 month time
point.
TIMP-1 was as efficient a marker as total or prostatic acid
phosphatase for predicting the occurrence of metastases, with
a diagnostic efficiency of 63%. Collagenase was a more
efficient marker (71%) though not as sensitive as alkaline
phosphatase (83%) or prostate-specific antigen (77%). How-
ever, raised serum TIMP-1 in combination with raised col-
lagenase provided a similar degree of diagnostic efficiency
(80%) as either alkaline phosphate or prostate-specific
antigen (Table II).
There was no correlation between Gleason grade and
serum levels of the metalloproteinases or their inhibitors
(data not shown).
Dicassion
In normal tissue matrix, turnover is low and metallo-
proteinase expression is not readily detectable, except during
tissue remodelling and wound healing. The restoration of
normal tissue structure requires a balanced interaction
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Figure 3 a, Collagenase, b, Stromelysin, c, TIMP-1 and d.
TIMP-2 levels (median and range) in patients with metastatic
(M1) and non-metastatic (MO) prostatic cancer, prior to and after
6 and 12 months' treatment.
b
between metalloproteinases and their inhibitors and matrix
synthesis (Hembry & Ehrlich, 1986; Chowcat et al., 1988;
Talhouk et al., 1992). There is evidence of the disregulation
of this balance in cancer, in which inappropriate expression
of metalloproteinase activity or its inhibition is thought to
facilitate tumour invasion and metastasis (Liotta et al., 1991).
We have investigated whether it is possible to monitor this
process by measuring levels of these enzymes and their
inhibitors in the serum of patients with cancer.
We have developed specific assays for serum collagenase
and stromelysin which primarily detect and are calibrated
against the proenzyme, but which also detect, at between 2-
and 8-fold reduced potency, the active enzyme and
enzyme-inhibitor complexes. Patient serum levels reported
here thus broadly reflect total serum collagenase and total
serum stromelysin levels respectively. We have also developed
specific assays for serum TIMP-1 and TIMP-2 in which the
predominant immunoreactive species is the free, non-
complexed inhibitor.
We have found that the serum levels of collagenase and
TIMP-1 are elevated in patients with prostatic cancer and
rheumatoid arthritis as compared with age-matched hospital
controls. Collagenase levels were significantly higher in pros-
tate cancer patients with metastases than in those without. In
the prostate cancer patients, treatment with buserelin led to a
fall in TIMP-1 and collagenase levels at 6 months. Col-
lagenase levels ained depressed at 12 months, but TIMP-1
returned to pretherapy values. In contrast, the concentration
of TIMP-2 was suppressed in the sera of patients with pro-
static cancer and elevated in the sera of patients with
rheumatoid arthritis -compared with the hospital control
group sera. During buserelin therapy TIMP-2 levels inversely
followed TIMP-1 levels, rising at 6 months and falling back
to basal levels at 12 months.
It is at present uncertain whether the collagenase and
TIMP-1 are tumour derived or result from stromal cell ex-
pression in response to tumour cell growth. In a previous
immunohistological study of these proteins in colorectal
cancer, antibody staining was shown to be localised to the
stromal cells and not to neoplastic epithelial cells (Hewitt et
al., 1991). In the case of gelatinase A and stromelysin 3,
recent results support the stromal expression hypothesis
since, although these enzymes were immunolocalised to
invasive tumours, the mRNA was shown by in situ hybridisa-
tion to be generated by surrounding stromal cells (Poulsom
et al., 1992; Pyke et al., 1992; Wagner et al., 1992; Muller et
al., 1993). In contrast, gelatinase A is found in tumour cells
(Stearns & Wang, 1993).
Few comparative studies on the quantitation of metallo-
proteinases and their inhibitors in cancer have appeared in
the literature. Collagenase and gelatinase A have been
measured in tissue homogenates derived from patients with
stomach carcinomas. Raised collagenase levels have been
found at the advancing tumour edge as compared with adja-
cent normal tissue. In contrast, gelatinase A levels show a
greater relative increase (Otani, 1990). TIMP-1 has been
examined in tissue extracts of colon cancer by competition
ELISA and shown to be raised between 1.3- and 18.9-fold in
31 cases compared with paired samples of adjacent normal
tissue (Lu et al., 1991). Our data show that TIMP-1 serum
Table II Predictive value analysis
Combined Alkaline Total acid Prostatic acid
TIMP-I Collagenase TIMP-J + phosphatase phosphatase phosphatase PSA
(nm} (nm) collagenase (IJL1- ) (IUtl-i (IU'-2) (ngml-')
n 35 35 35 35 32 32 31
Threshold value units 12.8 0.27 - 130 8.8 4.7 73
Positive predictive 73.7 80.0 85.7 94.4 72.2 72.2
value (%) 89.5
Negative predictive 50 60 71.4 70.6 46.7 46.7
value (%) 53.8
Diagnostic 62.9 71.4 80.0 82.9 65.6 65.6 77.4
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concentration is some 10-fold greater than combined levels of
collagnase and stromelysin for both cancer and control
groups. Taken together with the very low dissociation con-
stants (K,<lo-9 M) reported for the neutalisation of
activated metalloproteinase by TIMP-l (Murphy et al., 1989)
it is unlikely that either enzyme circulates in the active
form.
In contrast, much higher levels of elatinase A have been
reported, using ELISA, in normal human plasma (Zucker et
al., 1989) and in st IV lung carcnoma sera (Garbisa et al.,
1992). Our findings of mean serum TIMP-1 lvels of 9.8
(range 6.3-15.6) nM in a non-cancer control group and 12.9
(range 6.9-19.7) nM in prostate cancer patients indiate that
there may only be a small molar excess of non-complexed
inhibitor over potentially active gelatinase A in the circula-
tion.
There were significant difference in seru stromelysin
levels in the different groups studied. Patients with
rheumatoid arthritis were selected as controls in order to
assess differences between the destructive processes in cancer
and arthritides. It is diffiult to explain why serm
stromelysin was signicantly elvated in the rheumatoid
arthritis patients but not in the cancer patients. However;
there are reports of elevated levels of stromelysin in the
synovial fluid of patients with rheumatoid arthritis and
traumatic knee injury (Walakcovits et al., 1991). Taken
together with the results presented here, this idicates that
senim levels ofstromelysin may be a useful marker ofdisease
activity in inflammatory joint dissease. Our finding that the
molar ratio of collagenase to stromelysin was more than
4-fold elevated in patients with prostate cancer as compared
with patients with rheumatoid arthritis suggets that this
parameter may be a useful discriminatory marker in those
patients in whom one is trying to distinguish between
arthritis or metastatic cancer on the basis ofchanges in plain
radiographs or a bone scan.
Perhaps our most surprising fnding was that of raised
levels of TIMP-1 in cancer patients' serum as compared with
controls. It may be that this result represents a host response
to aggressive tumour growth. In primary lung carcinomas
TIMP-2 mRNA has been shown to be expressed by tumour
cells and surrounding stroma, whereas TIMP-l is mainly
expressed by the stroma (Urbanski et al., 1992). Our results
show that TIMP-2 serum levels are lower in prostate cancer
patients than in hospital controls and show an inverse pat-
tern to that of TIMP-1 during buserelin therapy. These are
consistent with the findings ofan increase in TIMP-1 mRNA
and a decrease in TIMP-2 mRNA foliowing transforming
growth factor (TGF) stimulation of a colorectal carcinoma
explant which led the authors to conclude that TIMP-1 and
TIMP-2 are independently regulated (Stetler-Stevenson et al.,
1990).
Whether the elevated serum levels of collagnase and
TIMP-1 reported here are a direct result oftheir involvement
in the mechanisms of malignancy in patients with metastatic
diseas or an effect resulting from host tissue responses, our
data suggest that the monitoring of these proteins in the
serum may be prognostic for metastatic burden. It is of
interest that a combination of high TIMP-l and collagnase
levels detected at presentation in our study showed a diag-
nostic effciency of 80% in predicting the occurrence of
metastasis - similar to that of alkaline phosphatase (83%)
and prostate-specific antigen (77%).
A similar proposal has been made by Garbisa et al. (1992),
who found a strong correlation between serum gelatinase A
levels and the presence of metastasis in lung cancer patients.
It is possible that the collagnase lvels are insufficent to
overcome the inhibitory levels of TIMP-1, but that the
greater levels of gelatinase A in the local environment of the
tumour may allow the type IV cleaving properties of this
enzyme to contribute to the metastatic phenotype. Recent
results with cell lines individually transfected with either
human collagenase or human gelatinase A genes suggest this
to be the case (A. Docherty, in preparation). We are cur-
rently investigating the role of gelatinase A in the develop-
ment of a metastatic phenotype through the use of synthetic
gelatinase inhibitors, in models ofmetastatic disease, together
with the development of specific quantitative assays for the
gelatinase isoenzymes.
We thank Jo Flanders, Claire Barton, Patrick Magill and Dawn
Butler.
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